Primiano, Esq.Vice President, General CounselKaryopharm Therapeutics Inc.2 Mercer RoadNatick, MA 01760Telephone: (508) 975-4820Patrick O'Brien, Esq.Ropes & Gray LLPPrudential Tower800 Boylston StreetBoston, MA 02199Telephone: (617) 951-7000Approximate date of commencement of proposed sale to the public:As soon as practicable after this Registration Statement is declared effective.If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to
definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.Large accelerated fileroAccelerated fileroNon-accelerated filerý(Do not check if asmaller reporting company)Smaller reporting companyoCALCULATION OF REGISTRATION FEEClass of Securities to be RegisteredNumber of Sharesto be Registered(1)Proposed MaximumOffering PricePer Share(2)Proposed MaximumAggregate Offering PriceAmount ofRegistration Fee(3)Common Stock, par value $0.0001 per share2,530,000$43.20$109,296,000$14,077.32(1)Includes
Being an Emerging Growth Company."Investing in the common stock involves risks that are described in the "Risk Factors" section beginning on page 15 of this prospectus.Per ShareTotalPublic offering price$$Underwriting discount(1)$$Proceeds, before expenses, to us$$Proceeds, before expenses, to selling stockholders$$(1)We
shares will be ready for delivery on or about                        , 2014.BofA Merrill LynchLeerink PartnersJMP SecuritiesWedbush PacGrow Life SciencesOppenheimer & Co.The date of this prospectus is                        , 2014.TABLE OF CONTENTSPageProspectus Summary1Risk Factors15Cautionary Note Regarding Forward-Looking Statements17Use of Proceeds18Price Range of Common Stock19Dividend Policy19Industry and Other Data19Capitalization20Principal and Selling Stockholders21Description of Capital Stock25Shares Eligible for Future Sale29Material U.S. Federal Tax Considerations for Non-U.S. Holders of Common Stock32Underwriting36Legal Matters43Experts43Where You Can Find More Information43Incorporation of Documents by Reference44You
themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States.Table of ContentsPROSPECTUS SUMMARYThis summary highlights information contained elsewhere in this prospectus or incorporated by reference into
for discovery, research, preclinical development and clinical trials of additional drug candidates; and the balance for working capital and other general corporate purposes.We will not receive any of the proceeds from any sale of shares by the selling stockholders.See "Use of Proceeds" for more information.NASDAQ Global Select Market symbol"KPTI"The
otherwise indicated, this prospectus reflects and assumes the following:•no exercise of the outstanding options described above;•no exercise by the underwriters of their option to purchase up to 330,000 additional shares of our common stock;
offering price of $41.37 per share, which is the last reported sale price of our common stock on The NASDAQ Global Select Market on June 24, 2014, after deducting underwriting discounts and
offering price of $41.37 per share, which is the last reported sale price of our common stock on The NASDAQ Global Select Market on June 24, 2014, after deducting underwriting discounts and
assumed public offering price of $41.37 per share, which was the last reported sale price of our common stock on The NASDAQ Global Select Market on June 24, 2014, but not including any
requirements of the Exchange Act.Equity PlansWe have filed a registration statement on Form S-8 under the Securities Act to register all shares of common stock subject to
the sale by affiliates in the public market, subject to compliance with the resale provisions of Rule 144.Registration RightsAs of March 31, 2014, the holders of 17,819,662 shares of our common stock or their transferees are entitled to various rights